Abstract 2013
Background
For liposarcoma (LPS), the mainstay of treatment is still surgical resection. Recently, some researchers suggested that immune checkpoint inhibitor may have a clinical activity in well-differentiated (WD) and dedifferentiated (DD) LPS. We aimed to evaluate the expression level of programmed death ligand 1 (PD-L1) and determine its relationship with clinical outcomes in WD/DD LPS.
Methods
All patients diagnosed with WD/DD LPS at Asan medical center from 1989 to 2017 were identified and their clinical information were obtained from our medical database. PD-L1 testing was performed with previously-collected surgery or biopsy tissue by Immunohistochemistry (IHC).
Results
Total 152 patients who were pathologically diagnosed with WD (n = 74) or DD (n = 78) LPS and had available tissue for PD-L1 IHC assay were included in this retrospective analysis. The median age was 58 years (range, 19—87) with males comprising 59.2%. By primary site, abdomen-pelvis (69.7%) was most frequently involved. Most patients (98.7%, n = 150) were presented with localized disease at the time of diagnosis and every patient with localized disease except one with high-perioperative risk (n = 149) underwent curative-intent surgical resection. PD-L1 positive (tumor proportion score ≥1%) rate was 31.1% and 51.3% in WD and DD LPS, respectively. In WD LPS, PD-L1 positivity, as well as abdomen-pelvis origin, R1/2 resection, and no adjuvant radiotherapy, was associated with shorter recurrence-free survival (RFS) (vs. PD-L1 negativity, 31.3 vs. 99.8 months; P = 0.014) and remained significant in the multivariate analysis (HR, 2.7, P = 0.028). In DD LPS, on the other hand, PD-L1 expression had no statistical significance in multivariate model for RFS. Overall survival was not properly compared due to the small number of death events.
Conclusions
Our findings indicate that decent portion of WD/DD LPS patients were positive for PD-L1 expression, and it might be a negative prognostic biomarker in surgically-resected WD LPS. This provides a rationale for future clinical trials of immune checkpoint inhibitor for patients with PD-L1-positive WD/DD LPS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract